Higher Delta variant-specific neutralizing antibodies prevented infection in close contacts vaccinated with ancestral mRNA vaccines during the SARS-CoV-2 Delta wave.

Autor: Goh YS; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore., Fong SW; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore., Tay MZ; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore., Rouers A; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore., Chang ZW; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore., Chavatte JM; National Public Health Laboratory, National Centre for Infectious Diseases, Singapore, Singapore., Hor PX; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore., Loh CY; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore., Huang Y; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore., Tan YJ; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore., Wang B; Singapore Immunology Network, A*STAR, Singapore, Singapore., Ngoh EZX; Singapore Immunology Network, A*STAR, Singapore, Singapore., Mohd Salleh SN; Singapore Immunology Network, A*STAR, Singapore, Singapore., Lee RTC; Bioinformatics Institute, A*STAR, Singapore, Singapore.; GISAID Global Data Science Initiative (GISAID), Munich, Germany., Lim G; Ministry of Health (MOH), Singapore, Singapore., Maurer-Stroh S; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.; National Public Health Laboratory, National Centre for Infectious Diseases, Singapore, Singapore.; Bioinformatics Institute, A*STAR, Singapore, Singapore.; GISAID Global Data Science Initiative (GISAID), Munich, Germany.; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Department of Biological Sciences, National University of Singapore, Singapore, Singapore., Wang CI; Singapore Immunology Network, A*STAR, Singapore, Singapore., Leo YS; National Centre for Infectious Diseases (NCID), Singapore, Singapore.; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.; Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore.; Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore., Lin RTP; National Public Health Laboratory, National Centre for Infectious Diseases, Singapore, Singapore.; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Lam MC; Ministry of Health (MOH), Singapore, Singapore., Lye DC; National Centre for Infectious Diseases (NCID), Singapore, Singapore.; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.; Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore., Young BE; National Centre for Infectious Diseases (NCID), Singapore, Singapore.; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.; Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore., Ng LFP; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore.; Health Protection Research Unit in Emerging and Zoonotic Infections, National Institute of Health Research, University of Liverpool, Liverpool, UK.; Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK., Renia L; A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), 8A Biomedical Grove, Immunos #05-13, Singapore, 138648, Singapore. renia_laurent@idlabs.a-star.edu.sg.; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore. renia_laurent@idlabs.a-star.edu.sg.; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore. renia_laurent@idlabs.a-star.edu.sg.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2023 Nov 07; Vol. 13 (1), pp. 19331. Date of Electronic Publication: 2023 Nov 07.
DOI: 10.1038/s41598-023-46800-x
Abstrakt: Identification of the risk factors and the high-risk groups which are most vulnerable is critical in COVID-19 disease management at a population level. Evaluating the efficacy of vaccination against infections is necessary to determine booster vaccination strategies for better protection in high-risk groups. In this study, we recruited 158 mRNA-vaccinated individuals during the Delta wave of SARS-CoV-2 infections in Singapore and examined the antibody profiles of infected individuals. We found that, despite high exposure due to communal living conditions in proximity, 4% of individuals (6/158) had PCR-confirmed infections and 96% (152/158) remained uninfected. Time-course analysis of the antibody profile at the start and the end of quarantine period showed Delta-specific boosting of anti-spike antibody response in 57% of the uninfected individuals (86/152). In the remaining 43% of the uninfected individuals (66/152) with no Delta-specific antibody boost, we found a higher Delta-specific antibody response at the start of quarantine period, which correlated with higher Delta pseudovirus neutralizing capacity. Our findings indicate that a higher basal variant-specific antibody response in the mRNA-vaccinated individuals contributes to better protection against infections by the new emerging SARS-CoV-2 variants.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje